This inventor holds 1 USPTO granted patent. Top assignees: Changzhou Le Sun Pharmaceuticals Limited, Changzhou Qianhong Biopharma Co., Ltd.. Active years: 2023.
Company Filing History:
1 out of 3 
1 out of 1 Years Active: 2023
Title: Liqun Jiang: Innovator in Protein Kinase Inhibition
Introduction
Liqun Jiang is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of selective inhibitors for protein kinases. His work is crucial in addressing proliferative disorders, including cancer.
Latest Patents
Liqun Jiang holds a patent for a tartrate of a selective CDK9 inhibitor and its crystal form. This patent, titled "Tartrate of selective CDK9 inhibitor and crystal form thereof," discloses a tartrate of 3-(5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)-benzenesulfonamide and a polymorph thereof. These compounds serve as inhibitors of protein kinases, specifically cyclin-dependent kinase 9 (CDK9), and are intended for the treatment of various diseases related to protein kinase/CDK activity.
Career Highlights
Throughout his career, Liqun Jiang has worked with prominent companies in the biopharmaceutical sector. He has been associated with Changzhou Qianhong Biopharma Co., Ltd. and Changzhou Le Sun Pharmaceuticals Limited. His expertise in the field has allowed him to contribute to innovative solutions in drug development.
Collaborations
Liqun Jiang has collaborated with several professionals in his field, including Shudong Wang and Hui Wang. These collaborations have further enhanced his research and development efforts in the biopharmaceutical industry.
Conclusion
Liqun Jiang's contributions to the field of protein kinase inhibition are significant, with his patent showcasing innovative approaches to treating proliferative disorders. His work continues to impact the biopharmaceutical landscape positively.